CervoMed Q2 net loss lower than estimates as costs drop
CervoMed Q2 net loss lower than estimates as costs drop
Overview
US biotech developer's Q2 net loss was lower than analyst expectations
Company completed $20.5 mln equity financings, extending cash runway through Q3 2027
Company prioritizing strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies
Outlook
Company aims to secure a partner to advance neflamapimod into Phase 3 for DLB
Company expects to present nfvPPA Phase 2a biomarker data in Q4 2026 and Q1 2027
CervoMed anticipates dosing first ALS patient in EXPERTS-ALS trial by end of 2026
Result Drivers
GRANT REVENUE DECLINE - Co said completion of Phase 2b RewinD-LB trial led to no grant revenue in Q2 2026, compared to $1.8 mln in Q2 2025
R&D EXPENSES LOWER - Co attributed decrease in R&D expenses to completed RewinD-LB trial and other clinical/nonclinical costs, offset by increased manufacturing and personnel costs
G&A EXPENSES LOWER - Co said decrease in G&A expenses was driven by lower headcount, severance costs, professional fees, and stock-based compensation
Company press release: ID:nGNX2k9Dpf
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss | Beat | $6.60 mln | $8.56 mln (6 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CervoMed Inc is $18.00, about 527.2% above its August 7 closing price of $2.87
Reuters Recommended Reads
Aug 7 - Soligenix Q2 net loss narrows as R&D expenses fall
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)